Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease

Imagem de Miniatura
Arquivos
art_CARNEIRO_Evaluation_of_10minute_postinjection_11CPiB_PET_and_its_2022.PDF (1.56 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRASILEIRA PSIQUIATRIA
Autores
GARCEZ, Alexandre Teles
Citação
BRAZILIAN JOURNAL OF PSYCHIATRY, v.44, n.5, p.495-506, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: Positron emission tomography (PET) allows in vivo evaluation of molecular targets in neurodegenerative diseases, such as Alzheimer's disease. Mild cognitive impairment is an intermediate stage between normal cognition and Alzheimer-type dementia. In vivo fibrillar amyloid-beta can be detected in PET using [11C]-labeled Pittsburgh compound B (11C-PiB). In contrast, [18F] fluoro-2-deoxy-d-glucose (18F-FDG) is a neurodegeneration biomarker used to evaluate cerebral glucose metabolism, indicating neuronal injury and synaptic dysfunction. In addition, early cerebral uptake of amyloid-PET tracers can determine regional cerebral blood flow. The present study compared early-phase 11C-PiB and 18F-FDG in older adults without cognitive impairment, amnestic mild cognitive impairment, and clinical diagnosis of probable Alzheimer's disease.Methods: We selected 90 older adults, clinically classified as healthy controls, with amnestic mild cognitive impairment, or with probable Alzheimer's disease, who underwent an 18F-FDG PET, early -phase 11C-PiB PET and magnetic resonance imaging. All participants were also classified as amyloid-positive or-negative in late-phase 11C-PiB. The data were analyzed using statistical parametric mapping.Results: We found that the probable Alzheimer's disease and amnestic mild cognitive impairment group had lower early-phase 11C-PiB uptake in limbic structures than 18F-FDG uptake. The images showed significant interactions between amyloid-beta status (negative or positive). However, early -phase 11C-PiB appears to provide different information from 18F-FDG about neurodegeneration.Conclusions: Our study suggests that early-phase 11C-PiB uptake correlates with 18F-FDG, irrespective of the particular amyloid-beta status. In addition, we observed distinct regional distribution patterns between both biomarkers, reinforcing the need for more robust studies to investigate the real clinical value of early-phase amyloid-PET imaging.
Palavras-chave
Positron emission tomography, amyloid, [11C]-labeled Pittsburgh compound B, perfusion, cerebral glucose metabolism, [18F]fluoro-2-deoxy-d-glucose, aging, neuroimaging
URI
https://observatorio.fm.usp.br/handle/OPI/50666
Referências
  1. Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007
  2. Bangen KJ, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00181
  3. Bilgel M, 2020, J CEREBR BLOOD F MET, V40, P288, DOI 10.1177/0271678X19830537
  4. BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797
  5. Blomquist Gunnar, 2008, Open Neuroimag J, V2, P114, DOI 10.2174/1874440000802010114
  6. Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014
  7. Busatto G, 2021, J NEUROSCI RES, V99, P481, DOI 10.1002/jnr.24739
  8. Busatto GF, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12122
  9. Ceccarini J, 2020, EUR J NUCL MED MOL I, V47, P2142, DOI 10.1007/s00259-020-04694-1
  10. Cohen AD, 2014, NEUROBIOL DIS, V72, P117, DOI 10.1016/j.nbd.2014.05.001
  11. Coutinho AMN, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0143-0
  12. Coutinho AM, 2020, EUR J NUCL MED MOL I, V47, P2715, DOI 10.1007/s00259-020-04933-5
  13. Coutinho AM, 2020, EUR J NUCL MED MOL I, V47, P2666, DOI 10.1007/s00259-020-04714-0
  14. Csukly G, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00052
  15. Daerr S, 2017, NEUROIMAGE-CLIN, V14, P77, DOI 10.1016/j.nicl.2016.10.005
  16. DISCHINO DD, 1983, J NUCL MED, V24, P1030
  17. Drzezga A, 2008, NEUROIMAGE, V39, P619, DOI 10.1016/j.neuroimage.2007.09.020
  18. Edison P, 2007, NEUROLOGY, V68, P501, DOI 10.1212/01.wnl.0000244749.20056.d4
  19. Faria DD, 2019, BRAZ J PSYCHIAT, V41, P101, DOI 10.1590/1516-4446-2017-0002
  20. Fjell AM, 2014, PROG NEUROBIOL, V117, P20, DOI 10.1016/j.pneurobio.2014.02.004
  21. Fodero-Tavoletti MT, 2009, J NUCL MED, V50, P198, DOI 10.2967/jnumed.108.057984
  22. FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
  23. Forsberg A, 2012, BBA-MOL BASIS DIS, V1822, P380, DOI 10.1016/j.bbadis.2011.11.006
  24. Fu LP, 2018, CONTRAST MEDIA MOL I, DOI 10.1155/2018/6830105
  25. Fu LP, 2014, EUR RADIOL, V24, P2800, DOI 10.1007/s00330-014-3311-x
  26. Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101
  27. Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
  28. Herculano-Houzel S, 2014, GLIA, V62, P1377, DOI 10.1002/glia.22683
  29. Herholz K, 2011, INT PSYCHOGERIATR, V23, pS25, DOI 10.1017/S1041610211000937
  30. Huang CW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19387-x
  31. Jack CR, 2019, JAMA NEUROL, V76, P1174, DOI 10.1001/jamaneurol.2019.1971
  32. Johnson KA, 2007, J NEUROL NEUROSUR PS, V78, P240, DOI 10.1136/jnnp.2006.096800
  33. Joseph-Mathurin Nelly, 2018, Alzheimers Dement (Amst), V10, P669, DOI 10.1016/j.dadm.2018.08.012
  34. Kaduszkiewicz H, 2014, ANN FAM MED, V12, P158, DOI 10.1370/afm.1596
  35. Kato T, 2016, AGEING RES REV, V30, P73, DOI 10.1016/j.arr.2016.02.003
  36. Kisler K, 2017, NAT REV NEUROSCI, V18, P419, DOI 10.1038/nrn.2017.48
  37. Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009
  38. Klunk WE, 2015, ALZHEIMERS DEMENT, V11, P1, DOI 10.1016/j.jalz.2014.07.003
  39. Laitinen L, 1989, CLIN NEUROL NEUROSUR, V91, P277
  40. Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162
  41. Lowe VJ, 2018, J NUCL MED, V59, P1583, DOI 10.2967/jnumed.117.204271
  42. Mattsson N, 2014, BRAIN, V137, P1550, DOI 10.1093/brain/awu043
  43. McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005
  44. Meyer PT, 2011, J NUCL MED, V52, P393, DOI 10.2967/jnumed.110.083683
  45. Minoshima S, 1997, ANN NEUROL, V42, P85, DOI 10.1002/ana.410420114
  46. Mosconi L, 2008, J NUCL MED, V49, P390, DOI 10.2967/jnumed.107.045385
  47. Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7
  48. Nihashi Takashi, 2007, Radiat Med, V25, P255, DOI 10.1007/s11604-007-0132-8
  49. Oliveira FPM, 2018, J ALZHEIMERS DIS, V65, P89, DOI 10.3233/JAD-180274
  50. Peretti DE, 2019, EJNMMI RES, V9, DOI 10.1186/s13550-019-0528-3
  51. Peretti DE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214187
  52. Peretti DE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211000
  53. Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985
  54. Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303
  55. Ponto LLB, 2019, J NEUROIMAGING, V29, P85, DOI 10.1111/jon.12582
  56. Price JC, 2005, J CEREBR BLOOD F MET, V25, P1528, DOI 10.1038/sj.jcbfm.9600146
  57. Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
  58. Rodell A, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00045
  59. Rodriguez-Vieitez E, 2016, J NUCL MED, V57, P1071, DOI 10.2967/jnumed.115.168732
  60. Rostomian AH, 2011, J NUCL MED, V52, P173, DOI 10.2967/jnumed.110.082057
  61. Silverman DHS, 2004, J NUCL MED, V45, P594
  62. Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040
  63. Smith SM, 2001, J COMPUT ASSIST TOMO, V25, P466, DOI 10.1097/00004728-200105000-00022
  64. Sojkova J, 2011, ARCH NEUROL-CHICAGO, V68, P232, DOI 10.1001/archneurol.2010.357
  65. Tiepolt S, 2016, EUR J NUCL MED MOL I, V43, P1700, DOI 10.1007/s00259-016-3353-1
  66. Tripathi M, 2013, INDIAN J NUCL MED, V28, P129, DOI 10.4103/0972-3919.119538
  67. Veronese M, 2015, J CEREBR BLOOD F MET, V35, P1771, DOI 10.1038/jcbfm.2015.120
  68. Zeydan B, 2019, ANN CLIN TRANSL NEUR, V6, P678, DOI 10.1002/acn3.741
  69. Zimmer ER, 2017, NAT NEUROSCI, V20, P393, DOI 10.1038/nn.4492

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/15
Artigos e Materiais de Revistas Científicas - LIM/21
Carregar mais